文献速递胸部肿瘤

获得EGFR激酶抑制剂耐药后免疫标志物表达的异质性:一例小细胞肺癌转化病例分析

Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation.
PubMed 文献 · J Thorac Oncol · 2017-02-11

报告一例76岁从不吸烟女性EGFR突变肺腺癌患者,吉非替尼耐药后尸检发现小细胞肺癌转化与EGFR T790M继发突变作为互斥耐药机制存在于不同转移灶中。比较两处肝转移(小细胞肺癌转化 vs 伴T790M的腺癌)和两处淋巴结转移的免疫标志物表达,发现PD-L1蛋白、间质PD-L1、CD8阳性T细胞浸润及基因表达谱均存在异质性。

要点

  • 伴T790M的腺癌病灶肿瘤细胞部分表达PD-L1蛋白,小细胞肺癌转化病灶肿瘤细胞不表达PD-L1。
  • 小细胞肺癌转化肝转移灶无间质PD-L1表达且肿瘤浸润淋巴细胞稀少,其他病灶有间质PD-L1染色和CD8阳性T细胞浸润。
  • 作者认为单一病灶活检标本可能不能代表所有病灶的免疫标志物状态。

核心结论

  • 免疫标志物表达依转移部位和组织学转化而存在异质性,来自一个病灶的活检标本可能不能代表所有病灶的免疫标志物状态。

研究设计与样本

  • 一例76岁从不吸烟女性EGFR突变肺腺癌患者吉非替尼耐药后死亡,尸检分析两处肝转移(小细胞肺癌转化 vs 伴T790M的腺癌)和两处淋巴结转移(小细胞肺癌转化 vs 伴T790M的腺癌),用免疫组化和免疫肿瘤基因表达panel比较免疫标志物表达状态。

主要发现

  • PD-L1蛋白在伴T790M的腺癌病灶肿瘤细胞中部分表达,在小细胞肺癌转化病灶肿瘤细胞中不表达。
  • 小细胞肺癌转化的肝转移灶无间质PD-L1表达且肿瘤浸润淋巴细胞稀少,其他病灶显示间质PD-L1染色和CD8阳性T细胞浸润。
  • 免疫肿瘤基因表达panel数据显示小细胞肺癌转化病灶中T细胞共刺激分子水平较高、I型干扰素调节基因表达较低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Expression of immune markers is of scientific interest because of their potential roles as predictive biomarkers for immunotherapy. Although the microenvironment of metastatic tumors and/or therapy-inducible histological transformation may affect the expression of these immune markers, there are few data regarding this context. METHODS: A 76-year-old never-smoking female with EGFR-mutated lung adenocarcinoma (AC) acquired resistance to gefitinib. After her death, an autopsy revealed SCLC transformation and EGFR T790M secondary mutation (T790M) as mutually exclusive resistance mechanisms occurring differently in different metastases; two liver metastases (SCLC versus AC with T790M) and two lymph node metastases (SCLC versus AC with T790M) were analyzed to compare the expression status of immune markers by immunohistochemistry and by an immune oncology gene expression panel. RESULTS: Programmed death ligand 1 (PD-L1) protein was partially expressed in tumor cells with AC lesions (T790M) but not in tumor cells with SCLC transformation. The liver metastasis with SCLC transformation showed no stromal PD-L1 expression and scant tumor-infiltrating lymphocytes, whereas the other lesions demonstrated stromal PD-L1 staining and infiltration of CD8-positive T cells. Data generated using an immuno-oncology gene expression panel indicated a higher level of T-cell costimulatory molecules and lower expression of type I interferon-regulated genes in lesions with SCLC transformation. CONCLUSION: These data highlight the heterogeneity of expression of immune markers depending on the metastatic sites and histological transformation and indicate that the biopsy specimen from one lesion may not be representative of immune marker status for all lesions.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Suda K, Murakami I, Yu H, et al. Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation. J Thorac Oncol. 2017. PMID: 28193529. doi:10.1016/j.jtho.2017.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。